Blog
RSS FeedPosted by Michael Wonder on 31 Aug 2025
FDA approval of Leqembi subcutaneous formulation charts path to combination therapies for Alzheimer's disease
29 August 2025 - Subcutaneous delivery increases accessibility and introduces potential for at home administration, following model of diabetes and ...
Posted by Michael Wonder on 23 Jun 2021
Evio Pharmacy Solutions established to tackle affordability, outcomes, and experience with medications
22 June 2021 - Privately funded venture will offer innovative medication solutions to patients, providers and customers. ...
Posted by Michael Wonder on 23 Jun 2021
Fees and charges: summary from 1 July 2021
23 June 2021 - The TGA is required to recover its costs for all activities that fall within the scope of ...
Posted by Michael Wonder on 23 Jun 2021
Rare disease patient advocates continue battle for affordable drugs
23 June 2021 - Beth Vanstone, mother of local Cystic Fibrosis Warrior Madi Vanstone and director of the CF Get ...
Posted by Michael Wonder on 23 Jun 2021
AstraZeneca to be phased out of Aussie jab rollout
23 June 2021 - The Melbourne-made AstraZeneca vaccine will be phased out of Australia’s COVID-19 jab rollout later this year. ...
Posted by Michael Wonder on 23 Jun 2021
TGA approves first generic pomalidomide
23 June 2021 - The TGA has approved first generic version of Celgene's Pomalyst. ...
Posted by Michael Wonder on 23 Jun 2021
Aducanumab (Aduhelm) information
22 June 2021 - The FDA has posted the CDER’s Office of Neurology’s Summary Review Memorandum describing the agency’s extensive ...
Posted by Michael Wonder on 23 Jun 2021
Price disclosure 2021 October cycle outcomes summary
23 June 2021 - The summary of price disclosure price reductions for the 2021 October cycle has now been published. ...
Posted by Michael Wonder on 23 Jun 2021
Genmab announces that Janssen has received European marketing authorisations for Darzalex (daratumumab) subcutaneous formulation, including for the treatment of patients with newly diagnosed light-chain amyloidosis
22 June 2021 - Janssen received European approval for Darzalex SC (daratumumab and hyaluronidase-fihj) in combination with bortezomib, cyclophosphamide and dexamethasone ...
Posted by Michael Wonder on 23 Jun 2021
LEO Pharma announces European Commission approval of Adtralza (tralokinumab) as the first and only treatment specifically targeting IL-13 for adults with moderate-to-severe atopic dermatitis
22 June 2021 - The European Commission regulatory approval is primarily supported by data from the ECZTRA 1, 2 and ECZTRA ...
Posted by Michael Wonder on 23 Jun 2021
Orpathys approved in China for patients with lung cancer and MET gene alterations
23 June 2021 - First-in-class approval in China in this setting and first regulatory approval for the oral, potent and ...
Posted by Michael Wonder on 23 Jun 2021
PBS listings to support patients with mesothelioma
23 June 2021 - From July 1, thousands of Australians and their families suffering from rare cancers and genetic disorders are ...
Posted by Michael Wonder on 22 Jun 2021
FDA approved Biogen Alzheimer’s drug despite some staff concerns
22 June 2021 - The agency has faced criticism for approving the drug, Aduhelm, without clear proof it works. ...
Posted by Michael Wonder on 22 Jun 2021
Australia-Canada-Singapore-Switzerland-United Kingdom (Access) Consortium
22 June 2021 - The TGA is a member of the Access consortium along with Health Canada, Health Sciences Authority of ...
Posted by Michael Wonder on 22 Jun 2021
New drug could cost the Government as much as it spends on NASA
22 June 2021 - The Alzheimer’s treatment will cost $56,000 per patient, and millions may use it. The result: “crazy numbers” ...
Posted by Michael Wonder on 22 Jun 2021
COVID-19 delta strain requires two vaccine doses for protection, Therapeutic Goods Administration boss says
22 June 2021 - Australians will need two doses of a COVID-19 vaccine to adequately protect themselves against the highly ...